2011 NLA Scientific Sessions Highlights
Clinical Trial Updates Impacting Your Practice
Philip J. Barter, MD, PhD
Prof. Barter reviews some recent trials with fibrates, statins, and niacin that he believes should have an impact on current clinical practice.
Tags:
What Do Simple Genetics Tell Us About Complex Diseases?
Jonathan C. Cohen, PhD
In the Keynote Presentation of the 7th Annual Scientific Sessions, Dr Cohen reviewed what "simple" genetics can tell us about coronary heart disease (CHD).
Tags:
The Impact of Prescription Switching on LDL-C Goal Attainment
JoAnne M. Foody, MD, FACC, FAHA
Dr Foody focused on the unintended consequences of formulary changes and the potentially harmful effects, with respect to providing evidence-based care or meeting therapeutic goals. She noted that in the United Kingdom (UK), forced switching of high-dose to low-dose statin resulted in higher rates of death, cardiac death, and non-cardiac death in individuals switched to the lower dose.
Tags:
Common Etiologies of Hypertriglyceridemia
Henry N. Ginsberg, MD
At least 95% of people with type-2 diabetes are insulin resistant. In the adipose tissue, insulin-resistant cells release fatty acids, increasing fatty acid flux to the liver resulting in transformation of the excess into triglycerides (TG)
Tags:
Genetic Susceptibility to Statin-Induced Myopathy
Georgirene D. Vladutiu, PhD
Severe statin myopathy is usually defined as severe muscle damage with damage to another organ, such as a kidney, and creatinine kinase (CK) ≥10 x upper limit of normal (ULN). However, some severely affected patients have serum CK <10 x ULN. Of 166 patients with severe statin myopathy referred to Dr Vladutiu's laboratory, 40% had CK ≥10 x ULN, 30% had CK 4-9 x ULN, and 10-15% had CK 2-3 x ULN.
Tags:
